1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Blackstone To Acquire CMIC As PE’s Japan Push Continues

Move Follows 2024 Delisting

 
• By Ian Haydock

Blackstone to buy leading Japanese CRO in latest move by a global private equity group to build a position in Japan’s life sciences space.

BlackStone CMIC Deal
Blackstone to acquire 60% of contract research organization CMIC as part of interest in Japan life sciences. (Shutterstock)

Private equity (PE) funds managed by Blackstone have entered into a definitive agreement to acquire 60% of Japan’s leading contract research organization (CRO) CMIC, in another major move by a US-based PE group to capitalize on opportunities within Japan’s life sciences sector.

The transaction follows closely in the wake of Bain Capital’s $3.4bn

Key Takeaways
  • US private equity group Blackstone is acquiring a majority stake in Japan's leading CRO CMIC.
  • CMIC said it is facing various challenges in the Japanese operating environment and wants to build links with foreign biotechs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.